Nektar Therapeutics | NKTR - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
ALKERMES USD 20.89M 8.62M 2026-03
Amgen USD 657M 4M 2026-03
Baxter International USD 58M 14M 2025-09
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 411M 21M 2026-03
Cara Therapeutics -89.64M 128.67M 2025-12
Cipla INR 131.3M 9M 2026-03
Dr.Reddys Laboratories INR 1.06B 113M 2026-03
Eisai JPY 1.55B 117M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
Grifols EUR 156.07M 31.46M 2025-09
Halozyme Therapeutics USD 5.51M 597K 2026-03
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Merck USD 479M 67M 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 343M 39M 2026-03
Pfizer USD 671M 40M 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Takeda JPY 43.65B 79.98B 2026-03
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Xencor USD 4.7M 2.65M 2026-03